463 related articles for article (PubMed ID: 21847708)
1. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.
Paprottka PM; Hoffmann RT; Haug A; Sommer WH; Raessler F; Trumm CG; Schmidt GP; Ashoori N; Reiser MF; Jakobs TF
Cardiovasc Intervent Radiol; 2012 Apr; 35(2):334-42. PubMed ID: 21847708
[TBL] [Abstract][Full Text] [Related]
2. Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver.
Abdelmaksoud MH; Louie JD; Hwang GL; Kothary N; Minor DR; Sze DY
J Vasc Interv Radiol; 2012 Mar; 23(3):323-30.e1. PubMed ID: 22277275
[TBL] [Abstract][Full Text] [Related]
3. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
[TBL] [Abstract][Full Text] [Related]
4. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.
Kennedy AS; Dezarn WA; McNeillie P; Coldwell D; Nutting C; Carter D; Murthy R; Rose S; Warner RR; Liu D; Palmedo H; Overton C; Jones B; Salem R
Am J Clin Oncol; 2008 Jun; 31(3):271-9. PubMed ID: 18525307
[TBL] [Abstract][Full Text] [Related]
5. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.
King J; Quinn R; Glenn DM; Janssen J; Tong D; Liaw W; Morris DL
Cancer; 2008 Sep; 113(5):921-9. PubMed ID: 18618495
[TBL] [Abstract][Full Text] [Related]
6. Radioembolization in patients with hepatic metastases from breast cancer.
Jakobs TF; Hoffmann RT; Fischer T; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Reiser MF; Helmberger TK
J Vasc Interv Radiol; 2008 May; 19(5):683-90. PubMed ID: 18440456
[TBL] [Abstract][Full Text] [Related]
7. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases.
Peker A; Çiçek O; Soydal Ç; Küçük NÖ; Bilgiç S
Diagn Interv Radiol; 2015; 21(1):54-9. PubMed ID: 25430526
[TBL] [Abstract][Full Text] [Related]
8. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases.
Cao CQ; Yan TD; Bester L; Liauw W; Morris DL
Br J Surg; 2010 Apr; 97(4):537-43. PubMed ID: 20205229
[TBL] [Abstract][Full Text] [Related]
9. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience.
Rhee TK; Lewandowski RJ; Liu DM; Mulcahy MF; Takahashi G; Hansen PD; Benson AB; Kennedy AS; Omary RA; Salem R
Ann Surg; 2008 Jun; 247(6):1029-35. PubMed ID: 18520231
[TBL] [Abstract][Full Text] [Related]
10. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.
Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H
J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059
[TBL] [Abstract][Full Text] [Related]
11. Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe.
Burgmans MC; Kao YH; Irani FG; Dames EL; Teo TK; Goh AS; Chow PK; Tay KH; Lo RH
J Vasc Interv Radiol; 2012 Oct; 23(10):1294-301. PubMed ID: 22922039
[TBL] [Abstract][Full Text] [Related]
12. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes.
Memon K; Lewandowski RJ; Mulcahy MF; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Gates VL; Atassi B; Newman S; Omary RA; Benson AB; Salem R
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):887-94. PubMed ID: 22137020
[TBL] [Abstract][Full Text] [Related]
13. Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors.
Michl M; Haug AR; Jakobs TF; Paprottka P; Hoffmann RT; Bartenstein P; Boeck S; Haas M; Laubender RP; Heinemann V
Oncology; 2014; 86(1):24-32. PubMed ID: 24401529
[TBL] [Abstract][Full Text] [Related]
14. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.
Bester L; Meteling B; Pocock N; Pavlakis N; Chua TC; Saxena A; Morris DL
J Vasc Interv Radiol; 2012 Jan; 23(1):96-105. PubMed ID: 22079516
[TBL] [Abstract][Full Text] [Related]
15. Optimization of radioembolic effect with extended-shelf-life yttrium-90 microspheres: results from a pilot study.
Lewandowski RJ; Riaz A; Ryu RK; Mulcahy MF; Sato KT; Kulik LM; Gates VL; Baker T; Omary R; Salem R
J Vasc Interv Radiol; 2009 Dec; 20(12):1557-63. PubMed ID: 19854068
[TBL] [Abstract][Full Text] [Related]
16. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option.
Saxena A; Bester L; Chua TC; Chu FC; Morris DL
Ann Surg Oncol; 2010 Feb; 17(2):484-91. PubMed ID: 19876691
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
Hendlisz A; Van den Eynde M; Peeters M; Maleux G; Lambert B; Vannoote J; De Keukeleire K; Verslype C; Defreyne L; Van Cutsem E; Delatte P; Delaunoit T; Personeni N; Paesmans M; Van Laethem JL; Flamen P
J Clin Oncol; 2010 Aug; 28(23):3687-94. PubMed ID: 20567019
[TBL] [Abstract][Full Text] [Related]
18. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization.
Murthy R; Kamat P; Nunez R; Madoff DC; Gupta S; Salem R; Yao JC
J Vasc Interv Radiol; 2008 Jan; 19(1):145-51. PubMed ID: 18192482
[TBL] [Abstract][Full Text] [Related]
19. Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.
Memon K; Kuzel TM; Vouche M; Atassi R; Lewandowski RJ; Salem R
Melanoma Res; 2014 Jun; 24(3):244-51. PubMed ID: 24638152
[TBL] [Abstract][Full Text] [Related]
20. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors.
Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W
J Gastroenterol Hepatol; 2017 Sep; 32(9):1617-1623. PubMed ID: 28132407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
